GHK-Cu Research Guide: The Copper Peptide Explained
Explore the copper-peptide complex behind Hero GHK-Cu: its structure, selected tissue-research studies, evidence gaps, vial formats, and laboratory concentration calculations.
Quick facts
| Compound | GHK-Cu |
|---|---|
| Peptide component | Glycyl-L-histidyl-L-lysine |
| Complex | GHK associated with copper(II) |
| Hero vial sizes | 50 mg and 100 mg |
| Research distinction | GHK, GHK-Cu, and copper salts are different test materials |
| Hero product | GHK-CU |
GHK-Cu is a copper-peptide complex built from the tripeptide glycyl-L-histidyl-L-lysine, abbreviated GHK, and copper. It appears in research on fibroblasts and extracellular matrix biology. The important starting point is its chemistry: the peptide and its copper complex should not be treated as interchangeable names.
Hero’s export contains GHK-Cu variants of 50 mg and 100 mg. The parent size attribute lists only 100 mg, so the catalog fields need reconciliation; this guide retains the two explicit variant records. This guide explains the molecule behind that entry, places selected primary studies in context, and describes what to check when documenting a laboratory preparation.
GHK-CU. View catalog product
Origin story: a tripeptide with an affinity for copper
GHK is a three-amino-acid sequence with affinity for copper(II). Early work examined the copper complex in cultured human fibroblasts and reported an effect on collagen synthesis. That finding concerned a defined cell-culture experiment, not a finished consumer product (Maquart et al., 1988).
The naming distinction matters in a literature search. GHK refers to the peptide; GHK-Cu specifies its copper-associated form. A study of copper-free GHK, a copper salt, or a modified GHK conjugate should retain that identity when summarized.
For a new experiment, use the paper’s materials section to determine what the investigators actually tested. Then compare those details with the supplied lot specification. A shared reference to copper peptides is not enough to establish a match.
How GHK-Cu is studied: chemistry meets cell biology
GHK-Cu is better introduced as a coordination complex than as a universal switch for a single receptor. Its composition creates experimental questions about the peptide, copper, and the conditions surrounding both. The measured biological endpoint must still be defined independently.
Useful comparisons may include peptide alone, an appropriate copper control, the complex, and a vehicle control, where justified by the hypothesis. These comparisons can help test whether a response depends on the chosen material rather than on one ingredient or a solvent difference.
Consider a collagen experiment. A collagen-related readout and a cell-number measurement answer different questions. More total signal might reflect a change in cellular activity, a change in viable cell number, or an assay effect. Controls help distinguish those possibilities.
The copper-peptide research explainer provides broader context. Keep the exact material, model, and endpoint attached whenever a paper’s findings are used to support a new experiment.
Key studies: cells and animal models are different layers
| Study | Model | Measured subject | Boundary |
|---|---|---|---|
| Maquart et al., 1988 | Cultured human fibroblasts | Collagen synthesis | A cell-culture finding, not a human cosmetic trial |
| Maquart et al., 1993 | Rat experimental wound chambers | Connective-tissue accumulation and biochemical measures | A specific animal model and preparation |
| Lot characterization | Supplied research sample | Stated identity and analytical results | Does not independently establish biological activity |
The rat wound-chamber study examined tissue accumulation in an experimental model. Its endpoints add a different layer of evidence from a cultured-cell measurement. They do not establish a human outcome for a research vial, nor do they validate an unrelated formulation (Maquart et al., 1993).
Reading the studies side by side is useful precisely because the models differ. Ask whether each measures synthesis, accumulated material, tissue structure, or function. These terms should not be collapsed into a single claim about regeneration.
Also record the comparator, duration, and sample preparation. A result reported under one set of conditions does not define the expected magnitude of an effect under another. It can motivate a hypothesis without pre-answering the new experiment.
Weak spots: where the evidence stops
FDA identifies limited human safety information and concerns involving aggregation and peptide-related impurities for injectable GHK-Cu preparations. That statement concerns the specified route and preparations; it should not be rewritten as a claim about every cosmetic or laboratory context (FDA, 2026).
As of November 17, 2026, the studies cited here do not establish an approved clinical use for Hero GHK-Cu. Research evidence about a molecule and authorization of a finished medicine are different questions.
Color is also an incomplete quality measure. Record appearance as an observation, but do not use it to assign identity, copper content, purity, or stability. A recognizable-looking solution is not a substitute for the relevant analytical result.
For experiments sensitive to metal composition, check whether the supplied documentation actually measures the property required. Do not assume a general HPLC/MS report establishes copper stoichiometry or an independent metal-content assay unless that testing is explicitly reported.
Handling GHK-Cu in the lab
The 50 mg and 100 mg options describe nominal material amounts. They do not specify solution concentration. Use the lot instructions and assay requirements to select compatible preparation conditions and an appropriate laboratory vessel.
For arithmetic only, nominal 50 mg at a final volume of 5 mL gives 10 mg/mL. Nominal 100 mg at the same final volume gives 20 mg/mL. These are calculations using a hypothetical final volume, not instructions to fill the supplied vial to that volume.
If an experiment requires molarity, use the molecular-weight basis appropriate to the documented material. Do not silently substitute the mass of copper-free GHK for the mass of the stated copper complex. Counterions and the reporting basis may also need clarification.
The concentration calculator helps check mass-per-volume arithmetic. The COA guide and testing explainer help interpret the complementary identity and purity information.
Hero’s supplied catalog identifies Northfield Analytical as its HPLC and mass-spectrometry testing partner. Match the actual report to the lot, and retain the preparation record. No specific purity percentage or unreported test result should be inferred from the general testing relationship.
GHK-Cu FAQ
Is GHK-Cu the same as GHK?
No. GHK names the tripeptide, while GHK-Cu identifies its copper complex. Their identities should remain distinct in research summaries and materials records.
Do fibroblast studies establish human skin or hair outcomes?
No. They describe responses in the tested cell system. A claim about a finished product or human outcome requires evidence addressing that specific question.
Does the 100 mg option have a stronger biological effect?
It lists more nominal material. Biological response depends on the prepared concentration, model, conditions, and measured endpoint, not vial size alone.
What is Hero GHK-Cu?
Hero GHK-Cu is Hero Peptides’ copper-peptide research material in 50 mg and 100 mg vials. Consult the product listing and matching lot documentation for supplied specifications.
GHK-CU. View catalog product
References
- Maquart FX, et al. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Lett. 1988;238(2):343-346. Source.
- Maquart FX, et al. In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ in rat experimental wounds. J Clin Invest. 1993;92(5):2368-2376. Source.
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Current page checked November 17, 2026. Source.
